SOURCE-LINKED INTELLIGENCE

Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development

CORDIS · observation · Publication date unknown

a new drug with the potential to stop and revert the disease, and to delay its onset. AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify patients with validated biomarkers. AT-001 is different in that it prevents aggregation of amyloid/tau proteins, common in many types of dementia. Phase IIa clinical trials have shown strong effects in the treatment of HCCAA. We will now carry out a registration trial for commercialization in Iceland and POC studies in Europe to obtain NDA in familial dementia, thereby informing the treatment of Alzheimer’s Disease (60% of dementia cases), potentially changing the lives of millions for the better. Precision medicine, big data,therapy,genomics,genetics, dementia,Alzheimer's disease,hereditary cerebral amyloid angiopathies,drug development,biobank

Read original source ↗ Open in workspace

recordType

award

status

CLOSED

region

EU

value

2500000

unit

EUR